Reduced total cellularity of fetal livers from PDGF-B−/− or PDGFRβ−/− E16.5 embryos
| Genotype . | Fetal liver cells (×106/liver) . | |
|---|---|---|
| E14.5 . | E16.5 . | |
| PDGF-B+/+ | 39.5 ± 3.4 | 73.1 ± 3.2 |
| PDGF-B−/− | 24.7 ± 5.7* | 45.1 ± 3.9† |
| PDGFR-β+/+ | ND | 79.2 ± 2.1 |
| PDGFR-β−/− | ND | 39.8 ± 16.1‡ |
| Genotype . | Fetal liver cells (×106/liver) . | |
|---|---|---|
| E14.5 . | E16.5 . | |
| PDGF-B+/+ | 39.5 ± 3.4 | 73.1 ± 3.2 |
| PDGF-B−/− | 24.7 ± 5.7* | 45.1 ± 3.9† |
| PDGFR-β+/+ | ND | 79.2 ± 2.1 |
| PDGFR-β−/− | ND | 39.8 ± 16.1‡ |
Fetal liver cells were collected from E14.5 and E16.5 embryos and stored on ice for 24 to 48 hours. The percentage of viable E16.5 fetal liver cells obtained from PDGF-B+/+ embryos (n = 3) and PDGF-B−/− mutants (n = 5) after 48 hours of storage was 75.0% ± 1.6% and 75.6% ± 1.1%, respectively. Viability of PDGFRβ+/+ and PDGFRβ−/−fetal liver cells was 80.6% (pool of 4 livers) and 81.9% (pool of 4 livers), respectively.
P = .0003;
P< .0001;
P = .002; n = 6 for all groups.